Recent Posts
- 2 self-reactive antibodies linked to higher relapse risk in AAV in study November 6, 2024
- Phase 3 trial of Tavneos enrolling children, ages 6-17, with AAV November 4, 2024
- Fasenra granted approval in EU for hard-to-treat EGPA patients October 30, 2024
- Combo maintentance therapy found more effective in severe EGPA October 28, 2024
- Alivexis’ MOD06051 shows promise as AAV therapy in rat model October 23, 2024
- Low ceruloplasmin protein linked to worse survival in anti-MPO AAV October 21, 2024
- ADX-097, potential AAV therapy, fares well in healthy volunteers October 16, 2024
- Long-term Nucala for EGPA eases disease activity, improves survival October 14, 2024
- Vasculitis Foundation launches new support group for young adults October 9, 2024
- AAV raises the risk of cardiovascular disease, review study finds October 7, 2024